Plus IPD spinout Monod Bio raises $25M, Clene looks to Phase III and updates from Gilead, Moderna, Novartis and more A month after activist shareholders of Radius Health Inc. (NASDAQ:RDUS) withdrew their proposed slate of directors that could have thwarted a proposed acquisition by Gurnet Point Capital and Patient Square Capital, the firms said Monday they have completed the $890 million deal. The $10-PER-SHARE price could be augmented by a $1-PER-SHARE contingent value right tied to sales of osteoporosis drug Tymlos abaloparatide. Activists Velan Capital Investment Management and Repertoire Partners had expressed little confidence in Radius’ strategic direction, including development of a cannabinoid therapy, but said July 12 the take-private deal “should allow stockholders to recoup a portion of the value that has been lost” under Radius’ current board. Radius will delist from NASDAQ. Monod Bio Inc., a spinout of University of Washington’s Institute for Protein Design (IPD), announced a $25 million seed round led by Matrix Capital, with participation from the Global Health Investment Corp., Cercano Management, The Washington Research Foundation, Boom Capital Ventures, Sahsen Ventures and Pack Ventures. The company’s modular biosensors, developed via computational protein design, can be used for multiple applications including point-of-care medical diagnostics, and have been described in Nature and Nature Biotechnology... More